Your browser does not support JavaScript capabilities, which maybe required to display this page properly.


PDF FormatRequires Adobe Acrobat Reader

Table 7.6i

Immunosuppression Use for Antirejection Treatment from Transplant

to One Year Following Transplantation, 1998 to 2007

Recipients with Pancreas After Kidney (PAK) Transplants

  Year of Transplant
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Transplants 156 220 305 305 375 344 420 343 293 261
Tx with Antirejection Treatments 44 57 65 45 43 61 59 46 32 33
Antibodies Any in Category 59.1% 75.4% 53.8% 60.0% 48.8% 65.6% 59.3% 76.1% 68.8% 72.7%
Atgam/NRATG/NRATS 9.1% 1.8% 1.5% 2.2% 0.0% 3.3% 0.0% 0.0% 0.0% 0.0%
OKT3 45.5% 63.2% 35.4% 26.7% 25.6% 13.1% 15.3% 13.0% 15.6% 12.1%
Thymoglobulin 2.3% 22.8% 21.5% 33.3% 30.2% 45.9% 44.1% 63.0% 59.4% 63.6%
Zenapax 2.3% 1.8% 1.5% 2.2% 2.3% 6.6% 0.0% 4.3% 3.1% 3.0%
Simulect 0.0% 0.0% 4.6% 4.4% 0.0% 4.9% 0.0% 2.2% 3.1% 0.0%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 27.9% 8.5% 6.5% 3.1% 6.1%
Corticosteroids Any in Category 70.5% 84.2% 87.7% 86.7% 90.7% 68.9% 79.7% 63.0% 68.8% 84.8%
Steroids 70.5% 84.2% 87.7% 86.7% 90.7% 68.9% 79.7% 63.0% 68.8% 84.8%
Antimetabolites Any in Category 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Methotrexate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%


Source: OPTN/SRTR Data as of May 4, 2009.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.



PDF FormatRequires Adobe Acrobat Reader